Skip to content
Clinical Trials – home
PortugalBack to Portugal

Clinical trials in Carregado – page 53

669 clinical trials in Carregado, Portugal. Every trial is listed in the EU Clinical Trials Register and updated daily.

PortugalOur site in PortugalEnsaios-Clinicos.pt(opens in a new tab)
Carregado at a glance
669
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

669 trials in Carregado

Open in trial search

Study on Selexipag and Bosentan for Children with Pulmonary Arterial Hypertension

Registered drug
Countries:PortugalPortugal
  • Participants:0–17 years
  • Substances:Bosentan
  • Sponsor:Actelion Pharmaceuticals Ltd.

Oesophageal carcinoma

Not recruiting

Study of Pembrolizumab in Patients with Esophageal Cancer Undergoing Chemoradiotherapy

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Merck Sharp & Dohme LLC

Hypertonic bladder

Not recruiting

Study on Overactive Bladder Treatment for Women Using Clostridium Botulinum Neurotoxin Type A and Vibe System

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:IncobotulinumtoxinA
  • Sponsor:Vensica Medical Ltd.

Study of Datopotamab Deruxtecan and Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer with Low PD-L1 Levels

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Daiichi Sankyo Inc.

Macular oedema

Not recruiting

Study on the Effects of RO7200220 for Adults and Children with Uveitic Macular Edema

InvestigationalNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Vamikibart
  • Sponsor:F. Hoffmann-La Roche AG

Netherton's syndrome

Not recruiting

Study to Evaluate the Effectiveness of Spesolimab in Treating Patients with Netherton Syndrome

Investigational
Countries:PortugalPortugal
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Spesolimab
  • Sponsor:Boehringer Ingelheim Espana S.A.

Acute kidney injury

Not recruiting

Study on Ravulizumab for Protecting Chronic Kidney Disease Patients from Acute Kidney Injury After Heart Surgery

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Ravulizumab
  • Sponsor:Alexion Pharmaceuticals Inc.

Hidradenitis

Not recruiting

Study to Evaluate the Effectiveness of Spesolimab for Patients with Moderate to Severe Hidradenitis Suppurativa

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Spesolimab
  • Sponsor:Boehringer Ingelheim Espana S.A.

Cardiac amyloidosis

Not recruiting

Study on Long-Term Safety of Eplontersen for Adults with Transthyretin-Mediated Amyloid Cardiomyopathy

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Ascorbic Acid
  • Sponsor:Ionis Pharmaceuticals Inc.

Parkinson's disease

Not recruiting

Study on BIA 28-6156 for Parkinson's Disease in Patients with GBA1 Gene Variant

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Pariceract
  • Sponsor:Bial R&D Investments S.A.

Bladder cancer

Not recruiting

Study of Pembrolizumab with Chemoradiotherapy for Patients with Muscle-Invasive Bladder Cancer

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Merck Sharp & Dohme LLC

Obesity+1

Not recruiting

Study on the Effects of Semaglutide for Weight Management in Children and Adolescents with Obesity or Overweight

Registered drug
Countries:PortugalPortugal
  • Participants:0–17 years
  • Substances:Semaglutide
  • Sponsor:Novo Nordisk A/S

Other cities in Portugal

The busiest research cities in the country

All 48 cities in Portugal

Clinical research in Carregado

What the registry says about research in the country

01 Nephrology Research

Research focusing on secondary hyperparathyroidism (SHPT) in patients undergoing hemodialysis. Clinical studies aim to evaluate new therapeutic approaches for managing hormone levels in patients with end-stage kidney disease (ESKD).

  • Hormone regulation in dialysis patients
  • SHPT treatment optimization
  • Renal replacement therapy outcomes

Studies evaluate novel treatments' efficacy in reducing parathyroid hormone levels in dialysis patients.

02 Cardiovascular Research

Investigations into atherosclerotic cardiovascular disease among dialysis patients, with particular focus on inflammatory markers. Studies examine the relationship between kidney disease and cardiovascular complications.

  • Cardiovascular outcomes in ESKD
  • Inflammatory biomarkers
  • Dialysis-related cardiovascular complications

Research aims to assess new treatments targeting inflammation in dialysis patients with cardiovascular conditions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.